State Medicaid programs spent $1.33 billion on hepatitis C treatments through the third quarter of last year, according to a Wall Street Journal analysis of federal data. The growth was, in part, thanks to Gilead's pricey yet highly effective drug, Sovaldi, which had a wholesale cost of $84,000 per person over the course of treatment. States spent a total of $1.08 billion on Sovaldi in the first nine months of 2014, representing 82 percent of all hepatitis C drug spending. New York spent the most on Sovaldi during the first nine months of last year--$297 million on the drug, or $47.50 per Medicaid enrollee--while California came in second and spent $86.94 million, or $7.29 per enrollee. Texas which has the nation's third largest-Medicaid population after New York and California, spent nothing on Sovaldi. Article